Abstract Predictive biomarkers are increasingly used to guide clinical trial design, diagnosis, and management of patients with neurodegenerative diseases. We profiled plasma from 632 ALS patients and 160 healthy controls using the NULISA CNS and Inflammation Panels and applied eXtreme Gradient Boosting (XGBoost) with nested cross-validation and SHapley Additive exPlanations (SHAP) to identify disease-associated proteins.
Eleanor Thomas
Get in touch with Eleanor
Contact Eleanor, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack